Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04624204). This is a study registration, not published results. Lead sponsor: Merck Sharp & Dohme LLC. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 672 participants (ESTIMATED). Conditions: Small Cell Lung Cancer. Interventions: BIOLOGICAL: Pembrolizumab 200 mg; BIOLOGICAL: Pembrolizumab 400 mg; DRUG: Pembrolizumab placebo (saline); DRUG: Pembrolizumab placebo (saline); DRUG: Olaparib 300 mg BID; DRUG: Olaparib matching placebo; DRUG: Etoposide 100 mg/m^2; DRUG: Platinum, investigator's choice; RADIATION: Standard Thoracic Radiotherapy; RADIATION: Prophylactic Cranial Irradiation (PCI). Primary outcome measures: Overall Survival: the time from randomization to death due to any cause , Up to approximately 82 months. Brief summary: Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.